Inhibikase Therapeutics(IKT)

Focus: Inhibikase Therapeutics is a public-stage biotech company focused on therapeutic vaccines and innovative treatments in infectious diseases and pulmonary arterial hypertension. The company operates with a lean R&D-focused model and minimal commercial infrastructure.

Infectious Diseases Vaccines

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Inhibikase Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Inhibikase Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$261K

Pipeline & Clinical Trials

Imatinib Mesylate

CML

PHASE_1

Clinical Trials (1)

NCT05623774A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg

Phase 1

Help build intelligence for Inhibikase Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline with Phase 3 asset (IKT-001 for PAH) offering potential near-term value creation and exit catalysts
Public company status provides liquidity and equity upside potential without early-stage startup volatility
Focused therapeutic area (vaccines + infectious disease) allows for deep specialization in growing markets

Watch Out For

Minimal cash runway relative to burn rate—FY2025 shows $98M cash against $17M annual R&D spend with $27.5M net loss, implying critical funding pressure
Zero open job postings and no disclosed headcount suggests severely constrained hiring and potential restructuring risk
Single-asset-dependent pipeline with IKT-001 Phase 3 trial representing majority of value; failure would be existential

Generated by Claude from Inhibikase Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

IkT-001Pro

Pulmonary Arterial Hypertension (PAH)

PHASE_2

Clinical Trials (1)

NCT06643143A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)

Phase 2

IKT-001

Pulmonary Arterial Hypertension

PHASE_3

Clinical Trials (1)

NCT07365332An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Cardiovascular

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Cardiovascular

2 pipeline

Marketed

Pipeline

Financials (FY2025)

R&D Spend

$17M26%

Net Income

-$28M

Cash

$98M

Source: SEC 10-K Filing